Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Feasible to prescribe ART to emergency department patients with suspected acute HIV infection

Empiric antiretroviral therapy (ART) for individuals presenting to emergency departments with suspected acute HIV infection (AHI) is highly feasible, investigators report in the July 1st edition of the

Published
08 July 2016
By
Michael Carter
New integrase inhibitor bictegravir looks promising in early studies

Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favourable pharmacokinetics, good tolerability, an improved resistance profile compared to older drugs in its class, and potent antiviral activity

Published
06 July 2016
By
Liz Highleyman
Atripla three times weekly maintains HIV viral suppression for 24 weeks

People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression

Published
05 July 2016
By
Liz Highleyman
The HIV Treatment Pipeline

“Depending on when you test positive for HIV, you could be looking at up to eight decades of treatment,” says Tim Horn of Treatment Action Group. “We need drugs that are gentler, kinder, better and cheaper.”

Published
28 June 2016
From
Poz
Antiretrovirals: A Success Story

Celebrating 20 years of effective HIV treatment - how antiretrovirals have improved since 1996 and the developments we still need.

Published
28 June 2016
From
Poz
PRO 140 antibody injections maintain viral suppression in phase 2 study

Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well tolerated and maintained undetectable viral load for more than a year after

Published
28 June 2016
By
Liz Highleyman
Gilead’s single tablet regimen Odefsey receives European marketing approval for HIV treatment

The European Commission has granted marketing authorization for Gilead Sciences' once-daily single tablet regimen (STR) Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients.

Published
27 June 2016
From
PharmaBiz
Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds

Taking efavirenz/tenofovir/emtricitabine (Atripla) three days a week maintained an undetectable viral load for at least 24 weeks in people who were already virally suppressed for at least two years, according to a small, proof-of-concept study presented at ASM Microbe 2016 in Boston, Massachusetts.

Published
22 June 2016
From
The Body Pro
WHO confirms antiretroviral therapy reduces the risk of life-threatening HIV-related infections

Adults and children with HIV who start antiretroviral therapy (ART) as early as possible reduce their risk of developing serious HIV-related infections, according to new findings published in the journal Clinical Infectious Diseases on 15 June 2016.

Published
22 June 2016
From
World Health Organization
Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early Study

A new integrase inhibitor known as bictegravir (BIC, GS-9883) was found to be well tolerated and effective as HIV treatment in a 10-day monotherapy study, warranting further investigation of the drug, according to research presented at ASM Microbe 2016 in Boston, Massachusetts.

Published
21 June 2016
From
The Body

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close